PLYX (Polaryx Therapeutics) ROE % Adjusted to Book Value: -2.02% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLYX Polaryx Therapeutics Inc PLYX
13 GF Score
Price $2.26
View Full Analysis

What is Polaryx Therapeutics ROE % Adjusted to Book Value?

Polaryx Therapeutics PLYX +2.73% 13 ROE % Adjusted to Book Value is -2.02% as of Mar. 2026. GuruFocus rates PLYX with a GF Score™ of 13/100.

Polaryx Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -288.56%. Polaryx Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 142.64. Polaryx Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -2.02%.

Polaryx Therapeutics ROE % Adjusted to Book Value Related Terms

Polaryx Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Polaryx Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polaryx Therapeutics ROE % Adjusted to Book Value Chart

Polaryx Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00

Polaryx Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -2.02

PLYX vs GUTS, NTHI, PEPG: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Polaryx Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Polaryx Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Polaryx Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Polaryx Therapeutics's ROE % Adjusted to Book Value falls into.


PLYX
13GF Score
Polaryx Therapeutics Inc PLYX
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polaryx Therapeutics ROE % Adjusted to Book Value Calculation

Polaryx Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-193.70% / N/A
=N/A

Polaryx Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-288.56% / 142.64
=-2.02%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -2.02% mean?
Polaryx Therapeutics (PLYX) has a ROE % Adjusted to Book Value of -2.02% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Polaryx Therapeutics and its competitors.
Is Polaryx Therapeutics' ROE % Adjusted to Book Value too high?
Polaryx Therapeutics' current ROE % Adjusted to Book Value is -2.02%. Overall, Polaryx Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Polaryx Therapeutics' ROE % Adjusted to Book Value compare to GUTS and NTHI?
Polaryx Therapeutics' ROE % Adjusted to Book Value of -2.02% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Polaryx Therapeutics and its competitors. Polaryx Therapeutics's current ROE % Adjusted to Book Value is -2.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaryx Therapeutics stock overvalued right now?
Polaryx Therapeutics (PLYX) has a current ROE % Adjusted to Book Value of -2.02%. The current ROE % Adjusted to Book Value is -2.02%. Polaryx Therapeutics' overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Polaryx Therapeutics (PLYX), the current ROE % Adjusted to Book Value is -2.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Polaryx Therapeutics Business Description

Address South Tower, 140 East Ridgewood Avenue, Suite 415, Paramus, NJ, USA, 07652
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
13GF Score

Get the complete analysis for PLYX

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.26
Price